Literature DB >> 11311656

Childhood cancer survival in Europe: an overview.

B Terracini1, J W Coebergh, G Gatta, C Magnani, C Stiller, A Verdecchia, A Zappone.   

Abstract

Other articles in this issue of the European Journal of Cancer have described population-based survival analyses of specific types of childhood cancer included in the EUROCARE database, diagnosed since 1979. The present paper summarises the relevant estimates and comments on intercountry differences, focusing on possible distortions in the intercountry comparisons based on data produced by the cancer registries. Potential biases include a lack of exhaustiveness of both case ascertainment and follow-up for living status and also a lack of consistency in the use of classification of the childhood cancer types. Nevertheless, despite such biases, consistent differences are observed between European countries in the probability of survival following the diagnosis of a paediatric cancer. In most cases, poor population-based survival rates are probably explained by inadequacies in the adoption and implementation of therapeutic protocols that have been proved to be effective. In some instances, the cause of unsatisfactory estimates was the inclusion of a sizeable proportion of children with cancer in clinical trials which were found to be ineffective. A regression analysis of incidence, mortality and survival rates during 1978-1989 over the whole EUROCARE database strongly indicates that the prognostic improvements over time are real and cannot be attributed to changes in diagnostic procedures.

Entities:  

Mesh:

Year:  2001        PMID: 11311656     DOI: 10.1016/s0959-8049(01)00044-2

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  5 in total

1.  Genomic imbalances in pediatric intracranial ependymomas define clinically relevant groups.

Authors:  Sara Dyer; Emma Prebble; Val Davison; Paul Davies; Pramila Ramani; David Ellison; Richard Grundy
Journal:  Am J Pathol       Date:  2002-12       Impact factor: 4.307

2.  Innovative Therapies for Children with Cancer pediatric phase I study of erlotinib in brainstem glioma and relapsing/refractory brain tumors.

Authors:  Birgit Geoerger; Darren Hargrave; Fabienne Thomas; Anna Ndiaye; Didier Frappaz; Felipe Andreiuolo; Pascale Varlet; Isabelle Aerts; Riccardo Riccardi; Timothy Jaspan; Etienne Chatelut; Marie-Cecile Le Deley; Xavier Paoletti; Christian Saint-Rose; Pierre Leblond; Bruce Morland; Jean-Claude Gentet; Valérie Méresse; Gilles Vassal
Journal:  Neuro Oncol       Date:  2010-10-25       Impact factor: 12.300

3.  Time trends and prognostic factors for survival from childhood cancer: a report from the Childhood Cancer Registry of Piedmont (Italy).

Authors:  Elisa Dama; Guido Pastore; Maria Luisa Mosso; Milena Maria Maule; Luisa Zuccolo; Corrado Magnani; Franco Merletti
Journal:  Eur J Pediatr       Date:  2006-01-13       Impact factor: 3.183

Review 4.  What can we learn from geographical comparisons of childhood cancer survival?

Authors:  K Pritchard-Jones; C Stiller
Journal:  Br J Cancer       Date:  2007-04-17       Impact factor: 7.640

5.  Leukemia cancer mortality trend in iran, from 1995 to 2004.

Authors:  Zeinab Fazeli; Mohamad Amin Pourhoseingholi; Mohsen Vahedi; Alireza Abadi; Fatemeh Sadat Fazeli Bavand-Pour; Ahmad Reza Baghestani
Journal:  Iran J Cancer Prev       Date:  2013
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.